ID119160021 / Ildong - LARVOL DELTA

ID11916, a novel androgen receptor antagonist with cGMP-dependent protein kinase activation for next-generation therapeutics in AR positive tumors (AACR 2025) - "In VCaP, where bicalutamide exhibited an agonistic effect, ID11916 showed approximately 60-fold greater anti-proliferative activity (IC50: 2.77 μM) than enzalutamide (IC50: 163 μM). In conclusion, our preclinical data introduce ID11916, a novel compound with a potential of overcoming resistance through both AR-dependent and AR-independent mechanisms by combining AR and PKG modulation. These findings support its potential as a next-generation AR-targeted therapy, offering an alternative to currently available AR targeting approaches."

Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor